Webcast: A guide to cancer clinical trials - From design to data
Dr. Susan Mayor & Dr. Frank Fleischer
00:00
A guide t...
0
1
427
00:16
Overview
16
2
428
00:56
Question ...
56
3
429
01:08
Characte...
68
4
430
03:13
Question ...
193
5
432
03:23
A well de...
203
6
433
04:37
Randomisa...
277
7
434
05:19
Well cont...
319
8
436
06:01
Question ...
361
9
437
06:16
Eligibili...
376
10
438
07:53
Trial siz...
473
11
439
08:49
So, how m...
529
12
440
09:39
Question ...
579
13
441
09:49
Endpoints...
589
14
442
10:24
Survival ...
624
15
443
11:40
Tumour-re...
700
16
444
12:37
Additiona...
757
17
445
13:39
What endp...
819
18
446
14:39
Question ...
879
19
447
14:47
Progressi...
887
20
448
15:24
Advantage...
924
21
449
16:49
Advantage...
1009
22
450
18:13
Example
1093
23
451
20:15
Question ...
1215
24
452
20:27
The need ...
1227
25
453
21:26
RECIST fe...
1286
26
454
23:04
RECIST me...
1384
27
455
24:43
RECIST
1483
28
456
25:16
Question ...
1516
29
457
25:25
Defining ...
1525
30
458
26:21
Key terms...
1581
31
459
26:48
What is n...
1608
32
460
28:10
Statistic...
1690
33
461
29:44
P-value
1784
34
463
30:58
P-value
1858
35
464
31:44
P-Value a...
1904
36
465
32:05
Confidenc...
1925
37
466
33:31
Survival ...
2011
38
467
34:24
Example K...
2064
39
468
36:01
Hazard Ra...
2161
40
469
37:15
Hazard Ra...
2235
41
470
38:09
Question ...
2289
42
471
38:26
1. Validi...
2306
43
472
39:32
2. Effica...
2372
44
473
41:11
3. Clinic...
2471
45
474
42:03
Question ...
2523
46
475
42:15
Complexit...
2535
47
476
43:26
Complexit...
2606
48
477
44:23
Question ...
2663
49
478
44:31
Future Ou...
2671
50
480
46:36
Summary
2796
51
481
Slide
0
/ 51
00:00 / 00:00